Go Deep
Chiome Bioscience Inc.
Chiome Bioscience Inc. Score & Ratio Trend
| Date | Score | P/E | P/B | D/E | Price |
|---|---|---|---|---|---|
| Oct 2026 | 17,866 | -7.0 | 4.77 | 0.04 | 55.69 |
| Oct 2026 | 17,741 | -7.2 | 4.87 | 0.04 | 56.80 |
Chiome Bioscience Inc. Quarterly Results
| Line Item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 |
|---|---|---|---|---|
| Revenue | 126,497,000.0 | 147,162,000.0 | 223,475,000.0 | 118,019,000.0 |
| Net Profit | -250,091,000.0 | -233,151,000.0 | -182,526,000.0 | -259,963,000.0 |
| EPS | — | -3.3 | — | — |
Chiome Bioscience Inc. Revenue & Profit: Last 5 Years
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
| Revenue | 593,290,000.0 | 780,809,000.0 | 682,464,000.0 | 630,815,000.0 | — |
| Net Profit | -982,779,000.0 | -1,020,776,000.0 | -1,220,018,000.0 | -1,242,871,000.0 | — |
| EPS | -17.5 | -17.5 | -24.6 | -28.3 | — |
Chiome Bioscience Inc. Balance Sheet
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
| Total Assets | 1,727,504,000.0 | 2,468,857,000.0 | 1,751,454,000.0 | 2,215,470,000.0 | — |
| Total Liabilities | 605,440,000.0 | 548,553,000.0 | 593,731,000.0 | 424,724,000.0 | — |
| Total Equity | 1,122,064,000.0 | 1,920,304,000.0 | 1,157,723,000.0 | 1,790,746,000.0 | — |
Owes vs Owns
Chiome Bioscience Inc. owed ¥0.18 for every ¥1 it owned in Jun 2026, down from ¥0.19 in Dec 2022.
| Period | Jun 2026 | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|---|
| Owes vs Owns | 0.18× | 0.35× | 0.22× | 0.34× | 0.19× |
Everything the company owes ÷ everything it owns. Below 1× it owns more than it owes; above 1× it owes more than it owns.
Chiome Bioscience Inc. Assets & Liabilities Breakdown (JPY millions)
What it owns — Dec 2025
Cash & short-term investments 69.8%Receivables 4.2%Inventory 2.9%Fixed assets (tangible) 9.5%Other assets 13.7%
How it's funded — Dec 2025
Short-term debt 5.0%Long-term debt 10.1%Payables 2.2%Other liabilities 17.7%Shareholders' equity 65.0%
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|
| Assets | ||||
| Cash & short-term investments | 1,205.0 | 2,063.3 | 1,325.6 | 1,727.3 |
| Receivables | 72.0 | 51.1 | 83.2 | 115.2 |
| Inventory | 49.4 | 46.2 | 64.1 | 71.5 |
| Fixed assets (tangible) | 164.5 | 112.8 | 114.0 | 115.2 |
| Intangible assets | 0.0 | 0.0 | 0.0 | 0.0 |
| Long-term investments | 0.0 | 0.0 | 0.0 | 0.0 |
| Other assets | 236.5 | 195.5 | 164.6 | 186.3 |
| Liabilities & equity | ||||
| Short-term debt | 86.7 | 281.5 | 291.0 | 184.0 |
| Long-term debt | 175.0 | 0.0 | 0.0 | 0.0 |
| Payables | 37.4 | 27.2 | 37.7 | 31.9 |
| Other liabilities | 306.3 | 239.9 | 265.0 | 208.9 |
| Shareholders' equity | 1,122.1 | 1,920.3 | 1,157.7 | 1,790.7 |
| Net tangible assets | 1,122.1 | 1,920.3 | 1,157.7 | 1,790.7 |
Chiome Bioscience Inc. Cash Flow
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
| Operating Activities | -935,988,000.0 | -1,000,695,000.0 | -1,069,192,000.0 | -1,191,009,000.0 | — |
| Investing Activities | -55,463,000.0 | 0.0 | 173,000.0 | 0.0 | — |
| Financing Activities | 133,198,000.0 | 1,738,421,000.0 | 667,303,000.0 | 1,127,291,000.0 | — |